Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay. Conference

Burrell, Matthew O, Stany, Michael, Rutledge, James et al. (2013). Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay. . JOURNAL OF CLINICAL ONCOLOGY, 31(15),

International Collaboration

cited authors

  • Burrell, Matthew O; Stany, Michael; Rutledge, James; Salom, Emery Manuel; Penalver, Manuel; Hallquist, Allan; Presant, Cary A

authors

date/time interval

  • May 31, 2013 -

publication date

  • May 20, 2013

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Chicago, IL

Conference

  • 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

publisher

  • LIPPINCOTT WILLIAMS & WILKINS

volume

  • 31

issue

  • 15